Myocyte Damage and Loss of Myofibers is the Potential Mechanism of Iron Overload Toxicity in Congestive Cardiac Failure in Thalassemia. Complete Reversal of the Cardiomyopathy and Normalization of Iron Load by Deferiprone

REFERENCES

• Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355(9220)2051–2052
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects of effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56–252, L1NAll, and their combinations. Curr Med Chem 2005; 12(23)2663–2681
   PubMed Web of Science ®Google Scholar
• Mavrogeni SI, Gotsis ED, Markussis V, Tsekos N, Politis C, Vretou E, Kremastinos D. T2 relaxation time study of iron overload in β-thalassemia. MAGMA 1998; 6(1)7–12
   PubMedGoogle Scholar
• Kolnagou A, Eracleous E, Economides Ch, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting excess cardiac iron loading and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin 2006; 30(2)219–227
   PubMed Web of Science ®Google Scholar
• Sonakul D, Pacharee P, Wasi P, Fucharoen S. Cardiac pathology in 47 patients with β thalassemia/Haemoglobin E. Southeast Asian J Trop Med Pub Health 1984; 15(4)554–563
   PubMedGoogle Scholar
• Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Totouzas PK. Myocarditis in β-thalassemia major. A cause of heart failure. Circulation 1995; 91(1)166–171
   Google Scholar
• Kyriacou K, Michaelides Y, Senkus R, Simamonian K, Pavlides N, Antoniades L, Zambartas C. Ultrastructural pathology of the heart in patients with β-thalassaemia major. Ultastruct Pathol 2000; 24(2)75–81
   PubMed Web of Science ®Google Scholar
• Iancu TC, Neustein HB. Ferritin in human liver cells of homozygous β-thalassaemia: ultrastructural observations. Br J Haematol 1977; 37(4)527–535
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions. Drug Saf 2003; 26(8)553–584
   PubMed Web of Science ®Google Scholar
• Hershko C, Bates GC, Bates BW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum fraction of potential toxicity. Br J Haematol 1978; 40(2)255–263
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002; 360(9332)516–520
   PubMed Web of Science ®Google Scholar
• Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 2003; 70(6)392–397
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith G C, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107(9)3738–3744
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Fessas Ch, Papatryphonas A, Economides Ch, Kontoghiorghes GJ. Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia. Br J Haematol 2004; 127(3)360–361
   PubMed Web of Science ®Google Scholar
• Telfer P, Coen PG, Christou S, Hadjigabriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980–2004. Haematologica 2006; 91(9)1187–1192
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Kolnagou A. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361(9352)184
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11(6)2161–2183
   PubMed Web of Science ®Google Scholar
• Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004; 103(5)1934–1936
   PubMed Web of Science ®Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Meleventi C, Di Gregorio F, Buratini MG, Terzoli S, Gabutti V. Survival and causes of death in thalassaemia major. Lancet 1989; ii(8653)27–29
   Google Scholar
• Halliwell B, Gutteridge JMC, Cross CE. Free radicals, antioxidants and human disease: where are we now?. J Lab Clin Med 1992; 119(6)598–620
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Jackson MI, Lunec J. In vitro screening of iron chelators using models of free radical damage. Free Rad Res Commun 1986; 2(2)115–124
   PubMedGoogle Scholar
• Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin 2006; 30(2)239–249
   PubMed Web of Science ®Google Scholar
• Cappelini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Prac Res Clin Haematol 2005; 18(2)289–298
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Effects of ICL670 (deferasirox) on cardiac iron concentrations. Lancet 2005; 366(9488)804
   PubMed Web of Science ®Google Scholar
• Huang YC, Chang JS, Wu KH, Peng CT. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in β-thalassemia major patients. Hemoglobin 2006; 30(2)229–238
   PubMed Web of Science ®Google Scholar